7:09 PM
 | 
Jun 05, 2007
 |  BC Extra  |  Top Story

Interim Avandia safety data released

A day ahead of a congressional hearing on FDA's handling of safety data for Avandia rosiglitazone, an independent DSMB released interim results from the ongoing RECORD study, which is designed to assess cardiovascular side effects of the diabetes drug from GlaxoSmithKline (LSE:GSK; GSK). The results from the GSK-sponsored study showed no significant difference in the primary endpoint, hospitalization...

Read the full 280 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >